Name (Synonyms) | Correlation | |
---|---|---|
drug2163 | SOC Wiki | 1.00 |
drug1748 | PTC299 Wiki | 1.00 |
drug1822 | Placebo Wiki | 0.06 |
There is one clinical trial.
In early December 2019, cases of pneumonia of unknown origin were reported in Wuhan, Hubei Province in the People's Republic of China. The disease spreads rapidly and the number of sick people is increasing. On January 3, 2020 a new virus of the coronavirus family is identified in samples of bronchoalveolar lavage fluid from a patient in Wuhan and subsequently confirmed as the cause of these pneumonias. On 7 January 2020, the World Health Organization (WHO) designated it as the new coronavirus 2019 (i.e. 2019-nCoV). On 11 February 2020, the WHO designated the disease associated with 2019-nCoV as coronavirus 2019 disease (COVID-19). On 12 March, WHO announced that the COVID-19 outbreak is a pandemic. As of March 24, 2020, more than 375,000 cases of COVID-19 had been diagnosed with more than 16,000 deaths attributed to this virus. (Ref WHO https://www.who.int/emergencies/diseases/novel-coronavirus-2019 ). In France, the number of cases rose from 105 cases at the end of February to 19615 confirmed cases on March 24. (Source Public Health France). Most of the cases are adults. However, children are not completely spared and serious cases have been described. These severe cases can be respiratory or extra-respiratory (e.g. myocarditis). We also know that pediatric and adult cases differ in terms of clinical, biological and imaging findings, particularly chest CT scans. However, the description of paediatric pictures, especially severe forms and the involvement of children suffering from co-morbidities, remains poorly reported. Finally, the risk factors for serious cases in children remain largely unknown. This observatory aim to describe the clinical phenotypes of hospitalized pediatric patients with Covid19 in France, according to age groups.
Description: requiring intensive care support or not
Measure: Clinical symptoms of children Time: at admissionDescription: requiring intensive care support or not
Measure: Clinical symptoms of children Time: day 14Description: requiring intensive care support or not
Measure: Biological results of children Time: at admissionDescription: requiring intensive care support or not
Measure: Biological results of children Time: day 14Description: requiring intensive care support or not
Measure: CT chest of children Time: at admissionDescription: requiring intensive care support or not
Measure: Pulmonary echography Time: Day 14Description: if available
Measure: nasopharynx sarscov2 load Time: at day 7Description: if available
Measure: nasopharynx multiplex PCR Time: at admissionDescription: days
Measure: number of hospital days Time: up to 6 months